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AbstrACt
Introduction Financial toxicity (FT) is a well-recognised 
problem in oncology. US-based studies have shown that: 
(a) cancer patients have a 2.7 times risk of bankruptcy; 
(b) patients who declare bankruptcy have a 79% greater 
hazard of death; (c) financial burden significantly impairs 
quality of life (QoL) and (d) reduces compliance and 
adherence to treatment prescriptions. The aim of the 
project is to develop and validate a patient-reported-
outcome (PRO) measure to assess FT of cancer patients 
in Italy, where, despite the universal health coverage 
provided by the National Health Service, FT is an emerging 
issue.
Methods and analysis Our hypothesis is that a specific 
FT measure, which considers the relevant sociocultural 
context and healthcare system, would allow us to 
understand the main determinants of cancer-related FT 
in Italy, in order to address and reduce these factors. 
According to the International Society for Pharmaco-
economics and Outcomes Research guidelines on 
PROs, the project will include the following steps: (1) 
concept elicitation (from focus groups with patients and 
caregivers; literature; oncologists; nurses) and analysis, 
creating a coding library; (2) item generation (using 
a format that includes a question and a response on 
a 4-point Likert scale) and analysis through patients’ 
cognitive interviews of item importance within different 
coding categories to produce the draft instrument; (3) 
factor analysis and internal validation (with Cronbach’s 
alpha and test–retest for reliability) to produce the final 
instrument; (4) external validation with QoL anchors 
and depression scales. The use of the FT measure in 
prospective trials is also planned.
Ethics and dissemination The protocol is approved by 
the ethical committees of all the participating centres. 
The project will tentatively produce a validated tool by 
the spring 2021. The project might also represent a 
model and the basis for future cooperation with other 
European countries, with different healthcare systems and 
socioeconomic conditions.
trial registration number NCT03473379.
IntroduCtIon
Financial problems are a matter of global 
attention in oncology, focusing on two levels 
of financial difficulties: third payer and indi-
vidual patient. Payers are generally affected 
by the rising cost of anticancer drugs.1 2 At 
the patient level, in the USA, co-payment 
is becoming unaffordable and, as a conse-
quence, cancer patients have higher likeli-
hood to file for bankruptcy than the general 
population.3 In addition, financial difficulties 
have been associated with lower patient satis-
faction,4 worse compliance,5 worse quality of 
life (QoL)6–8 and worse survival.9 Particularly, 
Ramsey and collaborators have shown that 
strengths and limitations of this study
 ► Previous research data support that financial prob-
lems affect the outcome of cancer patients in Italy, 
and despite an Italian healthcare system grounded 
on universal coverage, financial constraints may 
possibly affect cancer patient access to healthcare 
goods and services in the future.
 ► The way healthcare and welfare systems are struc-
tured impacts financial toxicity (FT) suffered by 
cancer patients, and instruments for describing and 
measuring FT need to be developed taking health-
care and welfare context into account.
 ► This protocol applies a widely accepted methodolo-
gy for the development of patient reported outcome 
measures.
 ► The rational of this protocol is that an instrument 
measuring cancer-related FT may be conducive 
to corrective policies that might ultimately benefit 
patients.
 ► For the same reasons that favour the development 
of a local instrument rather than the application of 
an existing tool developed elsewhere, one intrinsic 
limitation is that the instrument being developed will 
be properly applicable to Italian patients only.
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US cancer patients who declared bankruptcy have a HR 
of death of 1.79 (95% CI 1.64 to 1.96) as compared with 
a population of cancer patients who did not file for bank-
ruptcy and were matched in a propensity score analysis.9 
The problem is being reported in other countries and 
with varied types of healthcare systems.10–13
The need for specific tools to address this problem has 
been acknowledged in the scientific community, and in 
the USA a patient-reported-outcome (PRO) instrument, 
called ‘COST’, has been recently proposed for measuring 
financial distress.14 COST is a questionnaire composed 
of 11 items addressing psychological response to finan-
cial problems and coping behaviours. This questionnaire 
does not address material conditions that cause financial 
problems, and is highly specific for US context, where 
cancer diagnosis translates into an excess of out-of-pocket 
expenses.15 COST has been validated in some clinical 
settings, for example, in a series of 100 multiple myeloma 
patients after at least 3 months of medical treatment, in 
a series of 233 patients undergoing chemotherapy for 
solid tumours, and in a series of 191 Japanese patients 
receiving chemotherapy for a solid tumour for at least 2 
months.16–18 However, this questionnaire might not be 
sensitive to relevant issues in health systems where co-pay-
ment for anticancer drugs and other healthcare costs is 
not required.
On this ground, and cognizant of the challenges of 
cross-cultural applicability to the Italian cancer patient 
population, we initiated the development of a country 
specific tool to ensure highest possible content validity. 
In Italy, we have recently published that financial diffi-
culties exist and negatively affect the outcomes of cancer 
patients undergoing anticancer treatment, in terms of 
both QoL and life expectancy.19 We used the European 
Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 questionnaire in several clinical trials 
of treatment of solid tumours, promoted by the National 
Cancer Institute of Napoli during the last two decades. 
Therefore, taking advantage of the existing databases, 
we performed a pooled analysis of 16 trials including 
3670 patients, with the aims of exploring the relevance 
of financial difficulties in the Italian public healthcare 
system. We analysed question 28 of the EORTC QLQ-C30 
asking: “During the last week, has your physical condition 
or medical treatment caused you financial difficulties?”, 
with four possible response categories, from 1=‘not at 
all’ to 4=‘very much’. At baseline, 26% of the 3670 study 
patients reported a financial burden (response ≥2) that 
was associated with a higher chance of worsening global 
QoL response (OR 1.35, 95% CI 1.08 to 1.70, p=0.009). 
During treatment, out of 2735 patients who completed 
subsequent questionnaires, 616 (22.5%) developed finan-
cial toxicity (FT; worsening response as compared with 
the baseline) that was associated with a statistically signif-
icant higher risk of death (HR 1.20; 95% CI 1.05 to 1.37, 
p=0.007).19
The hypothesis underlying this project is that a specific 
instrument might help to describe and understand 
determinants and effects of cancer-related FT in Italy and 
that some of these determinants may be modified, ulti-
mately improving prognosis of cancer patients.
Therefore, the aim is to develop and validate a PRO 
instrument to describe and measure FT of Italian patients 
on cancer treatment, hereby described as ‘Patient 
Reported Outcome for FIghting Financial Toxicity of 
cancer’ (PROFFIT).
The impact of this project might be relevant for patients’ 
prognosis if we were able to understand how to intervene 
on FT, through adequate policies, because the size of the 
prognostic impact that we described in our preliminary 
study is similar to the magnitude of the benefit produced 
by several new drugs approved and reimbursed in Italy 
during the last few years.19 Therefore, the negative effect 
of FT, when occurring, may ultimately lessen the positive 
impact of some anticancer drugs; on the contrary, effec-
tive strategies contrasting FT, might synergise with anti-
cancer treatment and produce relevant benefit for cancer 
patients.
MEthods And AnAlysIs
The project will be conducted according to the method-
ology delineated by the International Society for Pharma-
co-economics and Outcome Research (ISPOR) Patient 
Reported Outcomes Content Validity Good Research 
Practices Task Force.20 21
The project includes five tasks, summarised in table 1.
task 1: concept elicitation and coding
Specific aim
To elicit concepts and coding them into a thematic library.
Context of use
Our preliminary data were obtained in a context of 
Medical Oncology units in public general hospitals, 
University Oncology units and public Cancer Institutes in 
Italy, where patients with specific types of solid tumours 
(lung, breast or ovarian cancer), mostly at an advanced 
stage of disease, underwent medical treatment, preva-
lently first-line therapy. In this project, the context will 
be expanded in order to include patients with any type of 
solid cancer or haematological malignancy who are under-
going or have recently completed medical treatment, 
including chemotherapy, target agents, immunotherapy, 
hormonal treatment, radiotherapy and combinations of 
such therapies.
Inclusion and exclusion criteria
The following are the major inclusion/exclusion criteria 
of the patients who will be involved in the project, also 
representing the target population for the use of the 
instrument in future studies.
Inclusion criteria
 ► Adult patients (>18 years).
 ► Histologically or cytologically confirmed diagnosis of 
any type of solid cancer or haematological malignancy.
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Table 1 Summary table of planned tasks
Title
Task 1 Task 2 Task 3 Task 4 Task 5
Concept 
elicitation and 
coding
Item generation 
and analysis
Instrument 
refinement and 
internal validation External validation
Application in 
clinical studies
Aim To elicit concepts 
and coding them 
into a thematic 
library.
To generate a 
draft version of 
the instrument.
To generate the 
final version of the 
instrument.
To generate data on 
external validity of 
the final instrument.
Use in prospective 
clinical studies.
Actions Literature review.
Focus groups 
with patients and 
caregivers.
Opinion of 
oncologists and 
nurses, through 
scientific societies.
Info points AIMAC 
(patients and 
caregivers).
Wording of 
items.
Importance 
analysis with 
patients (15 
patients per 
geographic 
region).
Item analysis 
with cognitive 
interviews of 
patients (15 
patients per 
geographic 
region).
Factor analysis.
Reliability analysis 
(Cronbach alpha, 
test–retest with 118 
patients).
Communication of 
results.
Correlation with 
anchors (EORTC 
QLQ-C30—namely 
Q28 and Q29 & 
30; HADS) and 
responsiveness; with 
patients.
Communication of 
results.
Promote and 
perform a large 
scale multicentre 
cross-sectional 
clinical trial.
Communication of 
results.
Psychologists 
involved
Yes, for focus 
group and coding 
activities.
Yes, for cognitive 
interviews and 
analysis.
No No No
Patients involved 30 divided in three 
focus groups and 
approximately 
25 for qualitative 
interviews.
90 (45 for 
importance 
analysis and 
45 for cognitive 
interviews).
118 based on sample 
size estimation.
220 based on sample 
size estimation.
1000 based on 
gross estimation.
Products Thematic library of 
concepts.
Paper reporting the 
protocol.
Pre-final 
instrument.
Paper reporting 
on qualitative 
research 
outcomes of the 
project.
Final instrument.
Paper presenting the 
final instrument.
Correlation with 
external anchors.
Paper reporting on 
validation.
Knowledge on 
prevalence and risk 
factors for FT in Italy.
At least one paper 
describing results of 
the cross-sectional 
study.
Duration 6 months 9 months 9 months 12 months 24 months
FT, financial toxicity; HADS, Hospital Anxiety and Depression Scale.
 ► Written informed consent provided.
 ► Medical treatment (chemotherapy, target agents, 
immunotherapy, hormonal treatment, radiotherapy 
or combinations of such therapies) ongoing or termi-
nated within the previous 3 months.
 ► Caregivers of patients who meet the above criteria.
Exclusion criteria
 ► Patients with major cognitive dysfunction or psychi-
atric disorders.
 ► Patients who have never received anticancer medical 
or radiation treatment.
Sources for concept elicitation
Four different sources of information will be used for 
concept elicitation.
Literature review
A literature review will be conducted including interna-
tional and Italian documents including scientific docu-
ments found through PubMed, CINAHL and EMBASE 
by cross checking references, and publicly available docu-
ments not cited in PubMed but found through patients’ 
advocacy websites, government agencies and common 
web research engines. Content will be divided in single 
items that will be subsequently categorised according to 
the conceptual framework.
Focus groups
Focus groups will be carried out in three towns, distrib-
uted in North, Central and South Italy. Two focus groups 
will be organised in each town: one with patients receiving 
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or having recently received medical anticancer treatment, 
and one with caregivers of patients receiving or who have 
recently received anticancer treatment. A maximum of 10 
individuals will be included, led by a skilled moderator 
with the help of an assistant moderator.22
All focus groups will be audio-recorded and transcribed 
verbatim. Content analysis will be conducted with a quali-
tative software (T-Lab). Qualitative analysis of focus group 
outcomes will be done using the constant comparison 
technique guided by the Grounded Theory approach.23 24
Expert opinions
Expert opinions will be sought through the cooperation 
with Associazione Italiana di Oncologia Medica, Collegio 
Italiano dei Primari di Oncologia Medica Ospedalieri, 
Federation of Italian Cooperative Oncology Groups 
(FICOG), Associazione Italiana Infermieri di Area Onco-
logica, using web or email surveys.
Interviews
Two types of interviews will be conducted. Patients and 
caregivers presenting at the info-points of Italian Asso-
ciation of Cancer Patients (AIMAC) in Italian hospitals 
in Northern, Central and Southern Italy will be invited 
to respond to question 28 of the EORTC QLQ-C30 ques-
tionnaire after a brief identification of baseline socio-
cultural characteristics. Those who reveal some degree 
of economic problem at question 28 (score ≥2), will be 
invited to participate in a brief semistructured interview 
to describe individual experiences of financial difficulties 
during cancer treatment. Sample size will be determined 
based on findings during ongoing qualitative analysis, in 
order to guarantee saturation, a point when the collec-
tion of new data does not shed any further light on the 
issue under investigation.
Qualitative interviews of consenting patients and 
caregivers will be conducted by nurses in three partici-
pating centres representing Southern (Naples), Central 
(Rome) and Northern (Turin) Italy, with the aim of 
exploring the lived experience of financial difficulties 
that occur during cancer treatment. The sample size will 
be defined by the principle of saturation (in order to 
guarantee the presence of patients and caregivers who 
have experienced the phenomenon), and to have demo-
graphic variability by region, sex, gender and age, when 
possible. It is estimated that 8–10 patients and caregivers 
from each centre will be adequate. Subjects participating 
in the interviews will have signed informed consent, be 
at least 18 years of age, have had experience of financial 
difficulty as a patient who has received cancer treatment, 
or as caregiver who has experienced financial difficulty 
while caring for a family member receiving treatment for 
cancer. Subjects with cognitive impairments or any phys-
ical or medical reason (ie, excessive fatigue) that would 
not permit participation in an interview will be excluded. 
Patients will be interviewed individually, and in private. 
Interviews will be audio recorded and later transcribed 
verbatim.
Coding and interpretation
Concepts collected through the analysis of the different 
sources will be coded in an iterative process with oppor-
tunities for data to be re-examined and reanalysed until 
no new codes or code groupings are identified and all 
passages from the transcripts have been assigned one 
or more codes. Redundancy and overlapping content 
will be controlled. Content comparison analysis will be 
also associated with the analysis of a qualitative software 
(eg, T-Lab), and concepts will be divided into different 
themes.
Data interpretation will flow upward from content 
comparison analysis, coding procedure results and 
data outputs from qualitative software. A quasi-statistics 
approach will be used to attain simple descriptive counts 
of categories, levels of consensus/dissent and about 
response patterns among the focus group members or the 
professionals responding to surveys and interviewees.22
Products and timelines of task 1
A list of concepts organised in a thematic coding library 
will be the product of task 1 activities, within 6 months 
from the beginning of the project. The protocol will be 
published to encourage debate and prompt cooperation 
with other European countries.
task 2: item generation and analysis
Specific aim
To generate a draft version of the instrument.
Criteria for item generation
Major criteria informing item generation are based on 
the prevalent characteristics of PRO instruments already 
available in Italian language and widely used in oncology 
(eg, EORTC questionnaires). Major criteria include:
 ► Item structure using a question/response model 
(rather than statement/agreement).
 ► Short questions.
 ► Simple language (avoiding technical words).
 ► No jargon.
Recall period
No single recall period is best for all measures or all 
phenomena.25 In the context of PROs, the recall period 
must correspond to the characteristics of the phenom-
enon of interest and the purpose of the assessment. 
Similar to the COST instrument, a 7-day recall period will 
be initially used.
Wording of items and responses
The formulation of each new item will respect the wording 
and the language suggested during the concept elicita-
tion phase in order to maintain a high level of fidelity and 
transparency.26 The response scheme will follow a 4-point 
Likert scale (not at all/a little/quite a bit/very much). 
Alternative formats will be explored, if needed.
Items will be reviewed separately by the members of 
the Steering Committee and a consensus will be sought 
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for each item, also checking for redundancy, overlapping 
content and ambiguous language.
Item importance analysis
Item importance will be ranked by a sample of 45 patients 
(15 for each centre, Naples, Rome and Turin, selected 
with the same inclusion/exclusion criteria reported 
above). Patients will be asked to score importance of 
items within each theme by using a 4-point Likert scale 
(not important at all/a little important/quite a bit 
important/extremely important). Within each theme, at 
least three items with the highest rank will be retained 
for subsequent steps.
Cognitive interviews
The list of items remaining after importance analysis, will 
be administered to a separate sample of 45 patients (15 
for each centre, Naples, Rome and Turin, selected with 
the same inclusion/exclusion criteria reported above) 
followed by cognitive interviews conducted by trained 
psychologists.27 The number of patients is based on a 
convenience sampling inspired by a grounded theory 
framework.24According to this framework, frequencies 
are rarely important, as one occurrence of the data is 
potentially as useful as many in understanding the process 
behind a topic, therefore, sample size should generally 
follow the concept of saturation.
Within such semistructured interviews, items will be 
evaluated for comprehensibility, recall, judgement and 
response, mapping a standardised feedback evaluation. 
Also, the structure and format of the instrument will be 
evaluated for readability, clarity of presentation, ease of 
administration. Consideration will be given to potential 
changes in mode of administration, as this study will eval-
uate the administration via tablet or smart phone. In this 
phase, criteria to retain, modify or reject items will be also 
based on missing values, item difficulty, discriminatory 
ability, comprehensibility and relevance.
Products and timelines of task 2
A draft instrument will be the product of task 2 and 
should be available by month 15. A paper focusing on the 
qualitative research outcomes of the first phases of the 
project is planned.
task 3: instrument refinement and internal validation
Specific aim
To generate the final version of the PROFFIT instrument.
Definition of scoring procedures
A global score deriving from the rough sum of the 
response scores at each item might be calculated, repre-
senting a continuous numeric measure of FT. However, in 
the definitive decision regarding scoring procedures, the 
Steering Committee will consider, in addition to a single 
composite measure, the production of subscores refer-
ring to different aspects of FT identified.
Factor analysis
To refine the instrument from the draft to the final 
version, a principal components analysis (explorative 
factor analysis) will be undertaken with data from the 
first field test (eigenvalue limit will be set at 1). Structural 
equation models could also be used to take into account 
causal variables.
Reliability
Internal reliability of multi-item scales will be assessed 
by analysing inter-item correlations and Cronbach’s α 
coefficient adjusted by the number of items. Estimates of 
α>0.70 will be considered acceptable, CIs will be provided 
by bootstrap methods.
To assess the test–retest reliability, the intraclass correla-
tion coefficient (ICC) will be estimated repeating the 
questionnaire administration within a week from the 
first use. With one-sided alpha 0.05, 80% power, a mini-
mally acceptable level of reliability equal to 0.70 and an 
expected ICC of 0.80, 118 patients are needed (10–12 for 
each centre, in 10–12 oncological centres distributed in 
North, Central and South Italy, selected with the same 
inclusion/exclusion criteria reported above).28
Products and timelines of task 3
The final instrument will be the product of task 3 and 
should be available by month 24. A paper presenting the 
final instrument is planned.
task 4: external validation
Specific aim
To generate data on external validity of the final PROFFIT 
instrument.
External validation
Criterion validity will be performed using different 
anchors. First, the correlation of PROFFIT with response 
to question 28 of the EORTC QLQ-C30 questionnaire 
will be assessed. Second, based on the assumption that a 
high degree of financial problems correlates with worse 
QoL, the correlation with the global health-related QoL 
EORTC score (questions 29–30) will be assessed. A similar 
analysis done with the COST score showed a Pearson 
correlation coefficient of 0.26.16 We plan to test correla-
tions with bilateral alpha 0.05, 80% power and expected 
Pearson correlation coefficient of 0.20. For this analysis, 
194 patients are required and around 220 patients will 
be enrolled to allow for some missing data. Descriptively, 
correlation of PROFFIT with the Hospital Anxiety and 
Depression Scale (HADS) will be studied as well. For this 
analysis, 20 patients will be enrolled for each centre, in 
10–12 oncological centres distributed in North, Central 
and South Italy; selection will be based on the same inclu-
sion/exclusion criteria reported above.
Responsiveness
To test responsiveness (to which extent the instrument 
is sensitive in capturing the changes of the variable of 
interest within-patients) repeated measures (at each cycle 
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Figure 1 Endpoint models for future use of PROFFIT. 
PROFFIT, Patient Reported Outcome for FIghting Financial 
Toxicity of cancer; QoL, quality of life.
or every 3–4 weeks) of PROFFIT will be collected together 
with the EORTC QLQ-C30.29 Changes over time will be 
estimated. Further correlation of PROFFIT with response 
to question 28 will be evaluated. Responsiveness will be 
longitudinally tested with the same sample of patients 
planned for criterion validity.
Products and timelines of task 4
Description of correlation of the final instrument with 
external anchors will be the product of task 4 and should 
be available by month 36. A paper will be submitted 
reporting the external validation data.
task 5: application in clinical studies
Specific aim
Use of PROFFIT in subsequent prospective patient 
series is the aim of task 5. This task is reported here for 
completeness. Specific protocols will be developed and 
will undergo proper approval once tasks 1–4 have been 
completed.
Endpoint models
PROFFIT may be used in at least three different endpoint 
models, depicted in figure 1.
Clinical study within the endpoint model 1
A large-scale multicentre cross-sectional observational 
study will be performed, where PROFFIT will be used to 
describe FT across a patient population defined according 
to type or stage of disease, or any other selection criteria.
The study will include patients with any type of solid 
tumours or haematological malignancy.
Specific aims will be:
 ► To describe prevalence of FT overall, and according 
to different subcategories (geographical, personal, 
socioeconomical, cancer-related, treatment-related).
 ► To describe the behaviour of PROFFIT within 
repeated measures over the time in patients under-
going medical treatment for cancer.
 ► To describe variability of psychometric properties of 
PROFFIT over the time.
 ► To describe the correlation between PROFFIT and 
typical endpoint of cancer treatments (eg, compli-
ance, QoL, survival).
The study will include at least 1000 patients and strat-
egies will be undertaken to include relevant categories 
in terms of gender, age, geographic location, type of 
cancer, performance status and type of treatment (classes 
of drugs, radiotherapy). During this phase, the coopera-
tion of major cooperative Italian groups (represented by 
the FICOG) will be of primary importance because it will 
guarantee feasibility with many participating centres.
Clinical study within the endpoint model 2
Endpoint model 2, studies might be proposed based on 
the content of PROFFIT instrument. According to the 
items that will be retained in the final instrument, we 
might be faced with different material conditions that 
may be cause of financial distress. All the efforts will be 
done to understand how such conditions can be exper-
imentally modified and prospective pilot studies will be 
planned to produce preliminary evidence on the possible 
efficacy of corrective actions. The number and the types 
of these trials will depend on the type of material condi-
tions listed in the PROFFIT.
Clinical study within the endpoint model 3
The planned use of the instrument in the endpoint model 
3 studies is more traditional. The instrument may be used 
as one of the elements analysed as secondary endpoint 
in trials testing the efficacy of new drugs or treatment 
strategies. In principle, consideration should always be 
given to the context of development of the instrument 
and therefore this model would apply to the Italian 
context only. Such studies might be implemented within 
this project, either based on the findings from previous 
phases or planned by other independent investigators, 
once PROFFIT has been made available to the Italian 
scientific community.
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Data collection procedures
The Unità Sperimentazioni Cliniche at Istituto Nazionale 
per lo Studio e la Cura dei Tumori Fondazione G. Pascale 
IRCCS manages a website ( www. usc- intnapoli. net) hub 
platform for the conduction of multicentre clinical trials, 
including facilities for patients registration, randomi-
sation, data collection through electronic case report 
forms, data management through an e-query system, and 
collection of radiological examination for independent 
review. Recently, the collection of PRO questionnaires 
from mobile devices has been implemented and will be 
used in this project. All website activities are fully tracked 
and verifiable and the whole system is under a quality 
assurance programme. The site is accessible by user-
name and password, and is protected through encrypted 
data certified by SSL and HTTPS protocols. From 2007 
to 2015, 180 000 web accesses have produced 216 000 
electronic case report forms. Data are managed by an 
in-house server, with regular backup, redundant features 
and onsite maintenance.
Therefore, patient registration and data collection will 
be centralised and web-based. Interviews, audio-visual 
data management will be analysed and transferred for 
storage by a dedicated software.
Patient and public involvement
The Steering committee of the protocol includes four 
representatives (FDL, LDC, EI, FT) of Italian and Euro-
pean patients’ associations (FAVO, AIMAC, ECPC) who 
meet regularly with all the other members and share all 
the decisions assumed by the committee. Therefore, they 
partnered for the design of the study, some of the activ-
ities performed in the concept elicitation phase, and in 
all the steps where the Steering Committee will assume 
decisions regarding the project. They will also be involved 
in dissemination and proposition of future studies using 
the PROFFIT instrument.
Project status
March 2018: start of tasks including patients (focus 
groups).
October 2019: planned time for submission of a paper 
reporting on qualitative tasks.
March 2020: planned time for final instrument 
availability.
March 2021: planned time for submission of a paper 
reporting on the final validated instrument (end of task 
4).
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